Health Condition 1: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis
Conditions
Interventions
Intervention1: Rituximab - single dose versus multiple dosage therapy: Patients with idiopathic membranous nephropathy will be randomized into two groups of which one group will receive single dose ri
Sponsors
NRS Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. biopsy proven membranous nephropathy 2. serologically anti PLA2R antibody positive 3. patients eligible for treatment as per standard protocol 4. patients who are willing to give consent
Exclusion criteria
Exclusion criteria: 1. presence of active sepsis 2. pregnancy 3. active malignancy 4. co-infection with HIV / Hep B / Hep C 5. prior treatment with any immunosuppressant therapy 6. presence of heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative number of patients who will experience both partial and complete remissionTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. eGFR at the completion of therapy 2. Change in serum albumin level 3. Change in lipid profile 4. Time required for complete or partial remission 5. Adverse effectsTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactArindam Kargupta
Department of Nephrology, NRS Medical College and hospital
Outcome results
None listed